Expression of Multidrug Resistance-associated Protein (MRP) in Human Gliomas

Overview

Journal J Neurooncol

Publisher Springer

Date 2001 Feb 24

PMID 11206006

Citations 30

Authors

M Mohri

H Nitta

J Yamashita

Affiliations

Soon will be listed here.

Abstract

Drug resistance is a major clinical problem in the chemotherapy of human gliomas. The multidrug resistance-associated protein (MRP), a membrane transporter related to non-P-glycoprotein multidrug resistance, is overexpressed in some drug-selected cancer cell lines. To investigate whether MRP is involved in the intrinsic drug resistance of human gliomas, surgical specimens of 20 gliomas (11 glioblastomas, 6 anaplastic astrocytomas, and 3 astrocytomas), 3 normal brain specimens, and 4 glioma cell lines (U87MG, U251MG, U373MG, and T98G) were analyzed. The expression of MRP was studied by RT-PCR and immunohistochemistry in the surgical specimens. The MRP expression levels in the cell lines were assessed by the quantitative RT-PCR and Western blot analyses. Sensitivity to adriamycin (ADM), etoposide (VP-16), cisplatin (CDDP), and 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU), were determined by MTT assay, and antisense treatment was evaluated in the cell lines. The expression of MRP was detected in 9 of 11 glioblastomas and 3 of 6 anaplastic astrocytomas. The quantitative analyses of the cell lines revealed that the MRP mRNA and protein levels were increased 4.5-fold in the T98G cells as compared to U87MG. T98G cells showed the highest resistance to all drugs. Western blot analysis revealed that treatment with the antisense oligonucleotide reduced the level of MRP expression to 25% of the sense oligonucleotide treatment in T98G cells. The sensitivity to ADM, VP-16 and CDDP was significantly increased in the antisense-treated cells as compared with the sense-treated cells. These results suggest that the MRP expression may be related to the intrinsic multidrug resistance in human gliomas.

Citing Articles

Potential of Natural Products in the Treatment of Glioma: Focus on Molecular Mechanisms.

Sheida A, Farshadi M, Mirzaei A, Najjar Khalilabad S, Zarepour F, Taghavi S Cell Biochem Biophys. 2024; 82(4):3157-3208.

PMID: 39150676 DOI: 10.1007/s12013-024-01447-x.

How Much is Enough? Impact of Efflux Transporters on Drug delivery Leading to Efficacy in the Treatment of Brain Tumors.

Zhang W, Oh J, Zhang W, Rathi S, Le J, Talele S Pharm Res. 2023; 40(11):2731-2746.

PMID: 37589827 PMC: 10841221. DOI: 10.1007/s11095-023-03574-1.

An Integrated Immune-Related Bioinformatics Analysis in Glioma: Prognostic Signature's Identification and Multi-Omics Mechanisms' Exploration.

Fan X, Zhang L, Huang J, Zhong Y, Fan Y, Zhou T Front Genet. 2022; 13:889629.

PMID: 35601497 PMC: 9114310. DOI: 10.3389/fgene.2022.889629.

Investigation of role of CpG methylation in some epithelial mesenchymal transition gene in a chemoresistant ovarian cancer cell line.

Alghamian Y, Soukkarieh C, Abbady A, Murad H Sci Rep. 2022; 12(1):7494.

PMID: 35523936 PMC: 9076839. DOI: 10.1038/s41598-022-11634-6.

Suppression of Proliferation of Human Glioblastoma Cells by Combined Phosphodiesterase and Multidrug Resistance-Associated Protein 1 Inhibition.

Kopanitsa L, Kopanitsa M, Safitri D, Ladds G, Bailey D Int J Mol Sci. 2021; 22(18).

PMID: 34575827 PMC: 8471536. DOI: 10.3390/ijms22189665.

References

Matsukura M, Shinozuka K, Zon G, Mitsuya H, Reitz M, Cohen J . Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci U S A. 1987; 84(21):7706-10. PMC: 299369. DOI: 10.1073/pnas.84.21.7706. View

Flens M, Izquierdo M, Scheffer G, Fritz J, Meijer C, Scheper R . Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res. 1994; 54(17):4557-63. View

Fillpits M, Suchomel R, Dekan G, Stiglbauer W, Haider K, Depisch D . Expression of the multidrug resistance-associated protein (MRP) gene in colorectal carcinomas. Br J Cancer. 1997; 75(2):208-12. PMC: 2063277. DOI: 10.1038/bjc.1997.35. View

Nakayama H, Yokoi H, Fujita J . Quantification of mRNA by non-radioactive RT-PCR and CCD imaging system. Nucleic Acids Res. 1992; 20(18):4939. PMC: 334261. DOI: 10.1093/nar/20.18.4939. View

Toth K, Vaughan M, Peress N, Slocum H, Rustum Y . MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. Am J Pathol. 1996; 149(3):853-8. PMC: 1865160. View

Chan H, Lu Y, Grogan T, Haddad G, Hipfner D, Cole S . Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein. Cancer Res. 1997; 57(12):2325-30. View

Schadendorf D, Makki A, Stahr C, Van Dyck A, Wanner R, Scheffer G . Membrane transport proteins associated with drug resistance expressed in human melanoma. Am J Pathol. 1995; 147(6):1545-52. PMC: 1869943. View

Flens M, Zaman G, van der Valk P, Izquierdo M, Schroeijers A, Scheffer G . Tissue distribution of the multidrug resistance protein. Am J Pathol. 1996; 148(4):1237-47. PMC: 1861521. View

Black S, Beggs J, Hayes J, Bartoszek A, Muramatsu M, Sakai M . Expression of human glutathione S-transferases in Saccharomyces cerevisiae confers resistance to the anticancer drugs adriamycin and chlorambucil. Biochem J. 1990; 268(2):309-15. PMC: 1131433. DOI: 10.1042/bj2680309. View

10.

Campling B, Young L, Baer K, Lam Y, Deeley R, Cole S . Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer. Clin Cancer Res. 1997; 3(1):115-22. View

11.

Kruh G, Chan A, Myers K, Gaughan K, Miki T, Aaronson S . Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene. Cancer Res. 1994; 54(7):1649-52. View

12.

Takano H, Kohno K, Ono M, Uchida Y, Kuwano M . Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res. 1991; 51(15):3951-7. View

13.

Noonan K, Beck C, Holzmayer T, Chin J, Wunder J, Andrulis I . Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A. 1990; 87(18):7160-4. PMC: 54703. DOI: 10.1073/pnas.87.18.7160. View

14.

Hara A, Yamada H, Sakai N, Hirayama H, Tanaka T, Mori H . Immunohistochemical demonstration of the placental form of glutathione S-transferase, a detoxifying enzyme in human gliomas. Cancer. 1990; 66(12):2563-8. DOI: 10.1002/1097-0142(19901215)66:12<2563::aid-cncr2820661219>3.0.co;2-a. View

15.

Nooter K, Herweijer H . Multidrug resistance (mdr) genes in human cancer. Br J Cancer. 1991; 63(5):663-9. PMC: 1972385. DOI: 10.1038/bjc.1991.152. View

16.

Jedlitschky G, Leier I, Buchholz U, Barnouin K, KURZ G, Keppler D . Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. 1996; 56(5):988-94. View

17.

Maier J, Voulalas P, ROEDER D, Maciag T . Extension of the life-span of human endothelial cells by an interleukin-1 alpha antisense oligomer. Science. 1990; 249(4976):1570-4. DOI: 10.1126/science.2218499. View

18.

Ishikawa T, Bao J, Yamane Y, Akimaru K, Frindrich K, Wright C . Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem. 1996; 271(25):14981-8. DOI: 10.1074/jbc.271.25.14981. View

19.

Krishnamachary N, CENTER M . The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res. 1993; 53(16):3658-61. View

20.

Grant C, Valdimarsson G, Hipfner D, Almquist K, Cole S, Deeley R . Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 1994; 54(2):357-61. View